Novo Nordisk A/S
Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and more
In this article MTB SATS PLTR UPS HIMS LOW HD Follow your favorite stocksCREATE FREE ACCOUNT A UPS worker checks an Amazon box to be delivered in New York. Eduardo Munoz | Reuters Check out the companies making headlines in premarket trading. Sagimet Biosciences — Shares of the biopharmaceutical company popped 31% following an upgrade […]
Read More
This under-the-radar biotech could be the next way to play the obesity drug boom
The lucrative market for obesity drugs is dominated by two players right now, but Structure Therapeutics has the potential to enter the category with an oral GLP-1 medication, according to Piper Sandler. Analyst Yasmeen Rahimi initiated coverage of the clinical stage drugmaker with an overweight rating on Thursday, and set a $58 price target, which […]
Read More
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020. Mike Blake | Reuters An Eli Lilly experimental drug helped patients lose about 26% of their weight on average following extended use or intensive lifestyle changes, according to results from two studies released Thursday. It’s the […]
Read More
UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk‘s Wegovy and Ozempic after some patients who took the treatments […]
Read More
Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images Danish pharmaceutical giant Novo Nordisk is set to launch its hugely popular Wegovy obesity drug in Germany this month, but it could be some time before […]
Read More
Morgan Stanley sees profound shift in diabetes treatment boosting opportunity for weight-loss drugs
Morgan Stanley analysts said they are seeing a profound shift in the way diabetes is being treated, with doctors intensifying the focus on weight management, which is accelerating the uptake of GLP-1 medications. What’s more, the analysts anticipate that over the next 24 months, this weight-centric approach will start to spread to other health complications […]
Read More
Morgan Stanley picks ‘particularly large conviction’ worldwide shares it suggests the rest of the marketplace is lacking
Morgan Stanley has named various get-rated world wide shares it expects to conquer the sector. In a notice to investors, it named shares following inquiring analysts to pick from a listing exactly where they have “specially significant conviction that the industry is not pricing the conquer” in phrases of the recent earnings bulletins. The lender […]
Read More
What investors need to know about weight loss medicines and suicide risk
Investors would be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week. Prior attempts to treat overweight or obese patients with medications were often plagued with side effects and drug recalls. Those earlier medications often didn’t seem like the results […]
Read More
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant’s weight loss treatment portfolio. Eli Lilly agreed to pay Versanis shareholders in […]
Read More
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Mike Segar | Reuters Uninsured Americans pay nearly $98 on average for a vial of Eli Lilly‘s generic insulin, even after the company pledged to cut the product’s list price to $25 per vial, […]
Read More